---
title: "Chrissy Teigen Joins Sanofi Campaign for Early Diabetes Testing"
description: "Chrissy Teigen has become the face of Sanofi's diabetes campaign, \"Screen for Type 1,\" aimed at promoting early screening for type 1 diabetes. Teigen's involvement follows her son Miles' diagnosis at "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/236763991.md"
published_at: "2025-04-21T10:00:00.000Z"
---

# Chrissy Teigen Joins Sanofi Campaign for Early Diabetes Testing

> Chrissy Teigen has become the face of Sanofi's diabetes campaign, "Screen for Type 1," aimed at promoting early screening for type 1 diabetes. Teigen's involvement follows her son Miles' diagnosis at age 6, highlighting the need for proactive health measures. Sanofi's Nadia Fontaine emphasized the importance of early detection to prevent serious complications. Additionally, Sanofi has committed $18 million to enhance diversity in clinical trials through partnerships with historically Black medical schools, aiming to improve healthcare representation and equity.

Chrissy Teigin is the new face of Sanofi’s diabetes campaign.1 The educational campaign is called Screen for Type 1, and it is focused on providing information about the importance of screening for the disease. According to Sanofi, blood tests can identify the condition before symptoms have begun to present themselves.

Teigen joined the campaign after her son Miles was diagnosed with the disease at just 6 years old. According to her, Miles briefly ended up in the hospital, and she hopes that by sharing her experiences as a mother that she can help other families avoid this.

In a press release, Teigen said, “Our family knew nothing about type 1 diabetes prior to 2024–and when I say nothing, I mean absolutely nothing. We were confused and scared when Miles was first diagnosed. Miles is a warrior–a type 1 diabetes warrior–and we are learning together every day how to help him manage this disease, but there is no doubt in my mind that knowing in advance would have made a positive impact for Miles, me, and our entire family. I want everyone to hear me when I say: stay proactive and talk to your doctor about getting yourself or your loved ones screened for type 1 diabetes today!"

In the same press release, Nadia Fontaine, head of US autoimmune type 1 diabetes franchise for Sanofi, added, “It's unacceptable that many people are still finding out about a type 1 diabetes diagnosis only when serious complications arise. We're energized to partner with Chrissy Teigen on the Screen For Type 1 movement and believe her story will strongly resonate with families and underscore the importance of early risk detection."

This is Sanofi’s latest endeavor to improve patient conditions. In October of last year, the company announced that it would be contributing $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine as part of the company’s goal of improving diversity in clinical trials.2

In a press release issued at the time, Sanofi’s senior vice president and global head of clinical trials and operations Lionel Bascles said, “At Sanofi, our mission is to chase the miracles of science to improve people's lives, and this means all people's lives, regardless of their race or ethnicity. By partnering with these three esteemed Historically Black College and University medical schools, we hope to facilitate new inroads to communities that have been underrepresented in healthcare for far too long. Increasing diversity and inclusion is essential to the research and development of medicines and vaccines for people of all backgrounds."

Valerie Montgomery Rice, MD, FACOG, president and CEO of the Morehouse School of Medicine added, “Morehouse School of Medicine is exceptionally grateful to Sanofi for this investment in our clinical study diversity Center of Excellence. We look forward to a robust partnership as we work to increase diversity in clinical studies and develop advanced opportunities for researchers, leading to greater health equity. More diversity in clinical studies will ensure traditionally underserved populations receive the very latest cutting-edge therapeutic innovations."

## Sources

1.  Chrissy Teigen - Author, Entrepreneur, Mom to Young Son with Type 1 Diabetes - Joins Sanofi's Screen For Type 1 Movement. *Sanofi*. April 15, 2025. https://www.prnewswire.com/news-releases/chrissy-teigen--author-entrepreneur-mom-to-young-son-with-type-1-diabetes--joins-sanofis-screen-for-type-1-movement-302426703.html
2.  Sanofi Commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to Increase Diversity in Clinical Studies. *Sanofi*. October 16, 2024. Accessed April 18, 2025. https://www.prnewswire.com/news-releases/sanofi-commits-18-million-to-howard-university-college-of-medicine-meharry-medical-college-and-morehouse-school-of-medicine-to-increase-diversity-in-clinical-studies-302276979.html

### Related Stocks

- [SNYNF.US - Sanofi](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 德克萨斯州起诉赛诺菲，指控其涉嫌通过'贿赂'医疗服务提供者来增加药品处方量 | 德克萨斯州检察长肯·帕克斯顿已对赛诺菲提起诉讼，指控该公司贿赂医疗服务提供者以推广其药物。诉讼称，赛诺菲的项目违反了德克萨斯州医疗保健计划欺诈预防法。帕克斯顿寻求超过一百万美元的经济赔偿和对进一步非法行为的禁令。这是继对赛诺菲及其他公司因类 | [Link](https://longbridge.com/en/news/276391061.md) |
| 艾可菲｜10-K：2025 财年营收 60.75 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276382538.md) |
| 科帕特｜8-K：2026 财年 Q2 营收 11.22 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276379291.md) |
| 百汇生命 REIT 首获星展 7200 万元社会贷款 并拟发行 7000 万元绿色债券 \| 联合早报网 | 百汇生命产业信托（Parkway Life REIT）从星展银行获得 7200 万新元的社会贷款，并计划发行 7000 万新元的绿色债券。这是其首次获得社会贷款和发行绿色债券，符合新推出的可持续融资框架。信托管理公司表示，所获资金将用于再融 | [Link](https://longbridge.com/en/news/276454669.md) |
| 全球财政刺激 “雷声大雨点小”？瑞银预计仅为 2026 年 GDP 增长贡献 8 个基点 | 瑞银研究指出，2026 年全球财政刺激实际影响接近中性，对 GDP 增长贡献仅约 8 个基点。尽管美、日、德等国法案热度高，但由于执行速度缓慢及新兴市场财政整固，实际力度远低于历史水平。全球经济仍需寻找内生动力，而非寄希望于政策红利。 | [Link](https://longbridge.com/en/news/276317126.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.